Locations:
Search
A growing body of evidence suggests that prolonged time to treat (TTT) can negatively impact survival for patients with solid tumors. A number of complicated factors contribute to prolonged TTT; the average even in our nation’s best academic cancer centers is 44 days.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Reducing this number is a daunting but doable task. Two years ago we began to emphasize TTT at Cleveland Clinic. We started with an overall TTT of 40 days, but by committing to multidisciplinary care and integrated practice and emphasizing and measuring TTT, we have achieved 30 days or less in our three largest cancer programs (breast, colorectal and lung).
Read more about how Cleveland Clinic reduced TTT in U.S. News & World Report.
Photo Credit: ©Russell Lee
Advertisement
Advertisement
Timing and type of side effects differ greatly from chemotherapy
Dedicated multidisciplinary teams support 84 ultra-rare cancers
Sessions explore treatment advances and multidisciplinary care
New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations
Early communication between oncologists and ophthalmologist warranted
Case-based course delves into latest treatment approaches
Long-term relationship building and engagement key to gaining community trust